Skip to main content

Table 2 Association between antidepressant use and breast cancer mortality

From: Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study

 

All patients (N = 23,669)

Prior depression (N = 5417)a

n

Person-years

Deaths

Unadjusted HR (95% CI)

Adjusted HRb (95% CI)

n

Person-years

Deaths

Unadjusted HR (95% CI)

Adjusted HR (95% CI)

All SSRIs combined

 Never

18,885

105,433

2539

Reference

Reference

2861

15,659

435

Reference

Reference

 Ever

4784

20,722

514

1.17 (1.07, 1.29)

1.27 (1.16, 1.40)

2556

11,216

294

1.09 (0.93, 1.26)

1.14 (0.98, 1.33)

 1–364 DDDs

2502

12,100

321

1.19 (1.06, 1.34)

1.28 (1.14, 1.44)

1055

5357

160

1.10 (0.92, 1.32)

1.15 (0.96, 1.38)

 365–1094 DDDs

1176

4992

109

1.02 (0.84, 1.24)

1.12 (0.93, 1.36)

701

3167

68

0.87 (0.67, 1.13)

0.91 (0.70, 1.19)

 1095–1824 DDDs

487

1847

47

1.37 (1.03, 1.84)

1.54 (1.15, 2.07)

333

1285

37

1.46 (1.04, 2.07)

1.58 (1.12, 2.24)

 1825+ DDDs

619

1782

37

1.32 (0.95, 1.84)

1.53 (1.10, 2.13)

467

1407

29

1.37 (0.92, 2.03)

1.54 (1.03, 2.29)

Tricyclic antidepressants

 Never

18,734

104,636

2505

Reference

Reference

3140

16,608

463

Reference

Reference

 Ever

4935

21,519

548

1.25 (1.14, 1.38)

1.30 (1.18, 1.43)

2277

10,267

266

1.08 (0.92, 1.25)

1.07 (0.92, 1.25)

 1–364 DDDs

4041

17,989

464

1.24 (1.12, 1.37)

1.29 (1.17, 1.43)

1583

7509

203

1.05 (0.89, 1.24)

1.06 (0.89, 1.25)

 365–1094 DDDs

574

2416

70

1.50 (1.18, 1.91)

1.51 (1.19, 1.92)

431

1865

53

1.32 (0.99, 1.77)

1.27 (0.94, 1.70)

 1095–1824 DDDs

170

661

9

0.82 (0.43, 1.58)

0.94 (0.49, 1.80)

140

521

6

0.65 (0.29, 1.46)

0.68 (0.30, 1.52)

 1825+ DDDs

150

454

5

0.75 (0.31, 1.81)

0.87 (0.36, 2.10)

123

372

4

0.71 (0.26, 1.92)

0.77 (0.29, 2.08)

Venlafaxine

 Never

22,826

122,227

2968

Reference

Reference

4976

24,830

684

Reference

Reference

 Ever

843

3928

85

1.02 (0.82, 1.26)

1.30 (1.04, 1.61)

441

2046

45

0.94 (0.69, 1.27)

1.03 (0.76, 1.40)

 1–364 DDDs

522

2531

66

1.19 (0.93, 1.51)

1.64 (1.28, 2.10)

214

1068

29

1.08 (0.74, 1.56)

1.32 (0.91, 1.92)

 365–1094 DDDs

161

861

11

0.60 (0.33, 1.09)

0.67 (0.37, 1.21)

105

557

9

0.67 (0.35, 1.29)

0.66 (0.34, 1.28)

 1095–1824 DDDs

68

293

2

0.36 (0.09, 1.43)

0.36 (0.09, 1.45)

47

227

1

0.22 (0.03, 1.57)

0.20 (0.03, 1.42)

 1825+ DDDs

92

243

6

1.55 (0.70, 3.46)

1.76 (0.79, 3.94)

75

194

6

1.94 (0.86, 4.37)

2.05 (0.91, 4.63)

  1. HR hazard ratio, CI confidence interval, SSRI selective serotonin reuptake inhibitor, DDD defined daily dose
  2. aRestricted to patients with a diagnosis of depression, or prescription of an antidepressant, in the year prior to cancer diagnosis
  3. bAdjusted for age, deprivation, year of diagnosis, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery, tamoxifen, aromatase inhibitors), comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, liver disease, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), hot flushes and pre-diagnosis use of hormone replacement therapy or oral contraceptives
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us